lnc-ANAPC1-7 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 9 of 9 results for "lnc-ANAPC1-7"
i
  1. Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis ClinicalTrials.gov

    ID: NCT01075152

    Description: The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal meningitis (CM) whether early initiation of antiretrovira...

    study.selectionCriteria: a: - Study entry prior to receipt of <7 days or >11 days of amphotericin therapy - History of prior, known cryptococcal meningitis - Inability to take enteral medication - Receiving chemotherapy or other immunosuppressant medications - Cannot or unlikely to attend regular clinic visits - Contraindication to immediate or delayed HIV therapy based on serious co-morbidities or co-infections, or laboratory values - Pregnancy or Breastfeeding - Female participants of childbearing potential who are participating in sexual activity that could lead to pregnancy must agree to use two re...
  2. A Phase I, Single Centre, Randomized, Open-Label, Three-Period Crossover Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and ... ClinicalTrials.gov

    ID: NCT02372344

    Description: The purpose of this study is to assess the effect of food timing on pharmacokinetics (PK) of AZD0585 and the effect of food timing on tolerabili...

  3. Central Auditory Processing Disorders Associated With Blast Exposure ClinicalTrials.gov

    ID: NCT00554801

    Description: The incidence of central auditory dysfunction in war fighters who are exposed to high-explosive blasts while serving in combat have not been cle...

    primaryPublication.ID: high-intensity blasts. J Rehabil Res Dev. 2012;49(7):1005-25....
  4. Toronto Thromboprophylaxis Patient Safety Initiative (TOPPS): A Cluster Randomized Trial ClinicalTrials.gov

    ID: NCT01869075

    Description: Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE, is one of the common and preventable complic...

  5. A Phase 1, Open-Label, Single Center, Single-Dose, Randomized, 4-Way Crossover Study to Assess the Effect of an Antacid on the Bioavailability of Febu... ClinicalTrials.gov

    ID: NCT02382640

    Description: The purpose of this study is to assess the effect of antacid administration, and its timing, on the bioavailability of a single dose of febuxost...

  6. Comparing Air Insufflation, Water Immersion and Water Exchange Methods During Minimal Sedated Colonoscopy, a Randomized, Controlled Trial ClinicalTrials.gov

    ID: NCT01535326

    Description: In minimally sedated Asian patients in a community setting the investigators showed that a limited volume of water infusion instead of air insuf...

  7. Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery ClinicalTrials.gov

    ID: NCT01337739

    Description: Patients undergoing deep sedation for outpatient procedures typically receive a combination of benzodiazepines, propofol, and opioids. Side effe...

  8. Effect of Healing Time on New Bone Formation Following Tooth Extraction and Ridge Preservation With Demineralized Freeze-Dried Bone Allograft ClinicalTrials.gov

    ID: NCT02154386

    Description: Bone grafting following tooth extraction is commonly performed to preserve bony ridge dimensions adequate to support subsequent implant placemen...

  9. A Pilot Biomarker Study of Oral Silybin-Phytosome Followed by Prostatectomy in Patients With Localized Prostate Cancer ClinicalTrials.gov

    ID: NCT00487721

    Description: Silibinin has demonstrated anti-cancer activity in the laboratory for several different cancer types, including prostate cancer. Silibinin was o...

    study.selectionCriteria: irubin less than or equal to 1.5 mg/dl 7. Planned prostatectomy as treatment for prostate cancer. 8. No known metastatic disease Exclusion Criteria: 1. Prior definitive treatment for prostate cancer with surgery or radiation therapy 2. Use of an investigational medication or device within one month of initiating study therapy. 3. Prior systemic chemotherapy for prostate cancer or any hormonal therapy for prostate cancer. 4. Any use of hormonal therapy (i.e. luteinizing hormone-releasing hormone analog) or a...

Displaying 9 of 9 results for "lnc-ANAPC1-7"